RxDoctor Payments Data

Thomas Dotson

Internal Medicine · Manassas, VANPI 1659356079

Payments from drug & device makers

$396in general payments, 2019–2025

Across 11 payments — averaging $35.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$194
  • Abbott$41
  • Exact Sciences$35
  • Pfizer$30
  • Otsuka America Pharmaceutical, Inc.$30
  • Biohaven Pharmaceuticals, Inc.$19
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$396 in reported general payments places this provider in the 65th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$254,464
Medicare patients
586
Services billed
2,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$140,085
EliquisApixaban68$67,064
JanuviaSitagliptin Phosphate64$66,359
JardianceEmpagliflozin41$58,565
XareltoRivaroxaban30$45,134
JanumetSitagliptin Phos/Metformin Hcl26$42,013
TradjentaLinagliptin26$38,857
RybelsusSemaglutide27$36,009
Tresiba Flextouch U-100Insulin Degludec48$32,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$29,895
TrulicityDulaglutide15$29,444
FarxigaDapagliflozin Propanediol17$23,693
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$19,216
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$18,478
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$15,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$176,094134 claims
PfizerEliquis$30$67,06468 claims
Lilly USA, LLCTrulicity$15$29,44415 claims
AstraZenecaFarxiga$194$23,69317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →